Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-03-01
|
| Series: | New Microbes and New Infections |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297521000019 |
| id |
doaj-3734452606734f989259ddc5c7fd05d3 |
|---|---|
| record_format |
Article |
| spelling |
doaj-3734452606734f989259ddc5c7fd05d32021-03-25T04:28:12ZengElsevierNew Microbes and New Infections2052-29752021-03-0140100837Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trialsP. Baindara0R. Chakraborty1Z.M. Holliday2S.M. Mandal3A.G. Schrum4Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO, USA; Corresponding author: P. Baindara, Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO, USA.Department of Biotechnology, North Bengal University, Darjeeling, IndiaPulmonary Disease, Critical Care Medicine, School of Medicine, University of Missouri, Columbia, MO, USACentral Research Facility, Indian Institute of Technology Kharagpur, Kharagpur, India; Corresponding author: S.M. Mandal, Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur, India.Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO, USA; Department of Surgery, School of Medicine, University of Missouri, Columbia, MO, USA; Department of Biomedical, Biological, & Chemical Engineering, College of Engineering, University of Missouri, Columbia, MO, USA; Corresponding author: A. Schrum, Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO, USA.Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems from an emerging understanding of the gut–lung axis wherein probiotic microbial species in the digestive tract can influence systemic immunity, lung immunity, and possibly viral pathogenesis and secondary infection co-morbidities. We review the principles underlying the gut–lung axis, examples of probiotic-associated antiviral activities, and current clinical trials in COVID-19 based on oral probiotics.http://www.sciencedirect.com/science/article/pii/S2052297521000019Coronavirus disease 2019gut–lung axisgut microbiomeprobioticssecondary infectionsevere acute respiratory syndrome coronavirus 2 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
P. Baindara R. Chakraborty Z.M. Holliday S.M. Mandal A.G. Schrum |
| spellingShingle |
P. Baindara R. Chakraborty Z.M. Holliday S.M. Mandal A.G. Schrum Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials New Microbes and New Infections Coronavirus disease 2019 gut–lung axis gut microbiome probiotics secondary infection severe acute respiratory syndrome coronavirus 2 |
| author_facet |
P. Baindara R. Chakraborty Z.M. Holliday S.M. Mandal A.G. Schrum |
| author_sort |
P. Baindara |
| title |
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials |
| title_short |
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials |
| title_full |
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials |
| title_fullStr |
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials |
| title_full_unstemmed |
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials |
| title_sort |
oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials |
| publisher |
Elsevier |
| series |
New Microbes and New Infections |
| issn |
2052-2975 |
| publishDate |
2021-03-01 |
| description |
Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems from an emerging understanding of the gut–lung axis wherein probiotic microbial species in the digestive tract can influence systemic immunity, lung immunity, and possibly viral pathogenesis and secondary infection co-morbidities. We review the principles underlying the gut–lung axis, examples of probiotic-associated antiviral activities, and current clinical trials in COVID-19 based on oral probiotics. |
| topic |
Coronavirus disease 2019 gut–lung axis gut microbiome probiotics secondary infection severe acute respiratory syndrome coronavirus 2 |
| url |
http://www.sciencedirect.com/science/article/pii/S2052297521000019 |
| work_keys_str_mv |
AT pbaindara oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials AT rchakraborty oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials AT zmholliday oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials AT smmandal oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials AT agschrum oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials |
| _version_ |
1724203953319575552 |